Q7. How do you engage with the EU institutions?
Alzheimer Europe engages with the EU institutions primarily, though not exclusively, through the European Parliament. For MEPs who have agreed to join the EAA, Alzheimer Europe keeps them updated with the latest developments, including hosting lunch debates within the parliament three times per year on different themes. Presently, 126 MEPs from 27 members states are members of the EAA.
Previously, we also engaged through the Expert Group on Dementia until, disappointingly, it was disbanded in 2018 by the European Commission. We will continue to use other platforms such as the Health Policy Platform and Commission consultations to engage with the institutions.
Q8. What are you doing in terms of raising awareness of national policies on dementia?
Alzheimer Europe has worked on this area in a number of different ways, including the creation and publication of the ‘Glasgow Declaration’ in 2014, calling for the creation of a dementia strategy in every country (as well as the creation of a European Dementia Strategy). Later this year, we will publish our 2018 Yearbook which will provide an overview of current national strategies, examining the similarities and differences in focus between the strategies.
In addition, we have previously (2012 and 2015) published the Alzheimer Europe Dementia Monitor, examining the status of dementia within countries across Europe, including in relation to policy, practice, healthcare provision and research.
Q9. How do you work with corporate sponsors and partners?
Alzheimer Europe works with members, partner organisations and sponsors in a number of different ways. One such way is our Company Round Table which serves as a platform for our members and sponsors to engage with each other, setting out their priorities and current work/projects, as well as sharing information and knowledge across a range of policy and practice matters. Alzheimer Europe accepts sponsorship for a number of its projects and activities but always ensures that the organisation keeps its complete independence as well as editorial and managerial control over its activities. All such sponsorship is always acknowledged transparently on our website. In addition, we often work with these partners on European funded projects, particularly through the Innovative Medicines Initiative (IMI2), including on AETIONOMY, AMYPAD, EPAD, MOPEAD and PARADIGM.
Q10. What is the balance in terms of responding to the policy agenda and coming up with your own
Naturally, Alzheimer Europe wishes to proactively set the dementia policy agenda to ensure it reflects the experiences and views of people with dementia, their families and carers, and where possible, involves them as equal partners in the process. To set this agenda, we carry out campaigning work such as the Glasgow Declaration, European Election Campaigns and the European Alzheimer’s Alliance. However, the nature of European policy process means that this is not always possible, meaning we sometimes have to work in a more reactive way, working with partner organisations to respond and shape policy and legislation. Alzheimer Europe does not solely interact with the European institutions, but also works on national policies such as care standards, guidelines for diagnosis and treatment or legal issues (e.g. advance directives, proxy-decision making systems, and informed consent) which are not on the agenda of the EU institutions.